Astellas Pharma announces FDA approval of XOSPATA.
On November 30th, 2018
Astellas Pharma US, Inc. is pleased to announce that the FDA has approved XOSPATA. XOSPATA is indicated for the treatment of adult patients who have relapsed or refractory acute myeloid leukemia (AML) with a FMS-like tyrosine kinase 3 (FLT3) mutation as detected by an FDA-approved test.1
An estimated 37% of AML patients have a FLT3 mutation and are considered at higher risk for relapsed or refractory
disease.2-4 Patients with relapsed or refractory FLT3m+ AML have limited therapeutic options and are challenging to treat.3,5
Astellas Pharma US, Inc. is pleased to announce that the FDA has approved XOSPATA. XOSPATA is indicated for the treatment of adult patients who have relapsed or refractory acute myeloid leukemia (AML) with a FMS-like tyrosine kinase 3 (FLT3) mutation as detected by an FDA-approved test.1
An estimated 37% of AML patients have a FLT3 mutation and are considered at higher risk for relapsed or refractory
disease.2-4 Patients with relapsed or refractory FLT3m+ AML have limited therapeutic options and are challenging to treat.3,5
No comments have been posted yet.